-
Mashup Score: 0Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis - Leukemia - 11 month(s) ago
Leukemia – Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis - Leukemia - 11 month(s) ago
Leukemia – Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
@AaronGoodman33 @ManniMD1 @VPrasadMDMPH Feels like a good place to drop our new article “Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials” - https://t.co/o5ZHZh0oxe
-
-
Mashup Score: 0
PURPOSE: The prognosis of elderly patients with diffuse large B-cell lymphoma (DLBCL) is worse than that of young patients. An attenuated dose of chemotherapy—cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-miniCHOP)—is a good compromise between efficacy and safety in very elderly patients. In combination with R-CHOP (R2-CHOP), lenalidomide has an acceptable level of…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Overall this study shows that r-miniCHOP can safely be given to many elderly patients with very good outcomes. Albumin may be a more important prognostic marker than age alone. https://t.co/dxyBQRsoSC
-
-
Mashup Score: 0Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Patterns and Outcomes in the Oldest-Old (≥85 years): A SEER-Medicare Database Analysis - 1 year(s) ago
INTRODUCTIONDiffuse Large B-cell Lymphoma (DLBCL) is most frequently diagnosed in the elderly, with a median age of presentation of 66 years. Anthracycline – ba
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
To help understand treatment patterns of patients 85 and older in routine clinical practice @paolocaimiMD, myself and a group of colleagues looked at linked SEER-Medicare data which we just presented at #ASH22 https://t.co/JPs2EtfbPa
-
-
Mashup Score: 0Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates - PubMed - 1 year(s) ago
Very elderly DLBCL patients have worse OS and PFS compared with younger patients but can achieve long term disease control and potentially be cured with chemoimmunotherapy. Older DLBCL patients treated with effective regimens do not have increased rates of relapse, but outcomes after relapse remain …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
We have previously published our retrospective data indicating patients over 80 can achieve long term disease control with antracyclines https://t.co/BWKniJ5Spq
-
-
Mashup Score: 0Evaluating Unconscious Bias: Speaker Introductions at an International Oncology Conference - 1 year(s) ago
PURPOSE In a professional setting, the introduction of female speakers without their professional title may have an impact on the public’s perception of the female speaker. We examined how professional titles were used during speakers’ introductions at the ASCO Annual Meeting. METHODS We conducted a retrospective, observational study of video-archived speaker introductions at the 2017 and 2018…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
@marklewismd @Dr_RShatsky Not just this meeting, not just this panel. "Female speakers were more likely to be introduced by first name only (17% v 3%; P < .001)" https://t.co/HgzgJNaKqg
-
-
Mashup Score: 7PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR - 1 year(s) ago
To the editor:
Source: American Society of HematologyCategories: Expert Picks, Latest HeadlinesTweet-
In this case report there was clinical response as well as increased in detectable CAR DNA levels post PDL1 therapy https://t.co/cP1SYBRGCH
-
-
Mashup Score: 0
General Sessions Session: Plenary Scientific Session Sunday, December 11, 2022, 2:00 PM-4:00 PM Hall E (Ernest N. Morial Convention Center) Martin Dreyling, MD1, Jeanette K. Doorduijn, MD, PhD2, Eva Gine, MD, PhD3, Mats Jerkeman, MD, PhD4, Jan Walewski, MD5, Martin Hutchings, MD, PhD6*, Ulrich Mey, MD7,8, Jon Riise, MD, PhD9*, Marek Trneny, MD10, Vibeke K.J. Vergote11*,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Exciting frontline changes headed towards MCL at #ASH2022 - Triangle Study being presented as a Plenary Session. I had a hard time following the schema so created a few slides... 1/11 https://t.co/lZfu020wY5
-
-
Mashup Score: 0
Many of the things we’re told to do for our dental health aren’t supported by systematic reviews.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet-
@AaronGoodman33 Once I started learning EBM in Med school, questioning the utility of a routine physical, I became very skeptical of necessity for dental exams in absence of pain. Found this some years back: https://t.co/VQ0cFDILgw
-
-
Mashup Score: 63.87 Round Table on Multiple Myeloma Initial Therapy, High Risk, and Maintenance — Plenary Session - 2 year(s) ago
Today we try something new. We’re joined by five esteemed multiple myeloma experts for a back-and-forth round table discussion on the disease, including initial therapy, high risk, and maintenance. Our guests are Dr. Raj Chakraborty of Columbia University, Dr. Sam Rubinstein of the University of Nor
Source: Plenary SessionCategories: Hem/Oncs, Latest HeadlinesTweet-
excellent and respectful debate on treatment of myeloma on @Plenary_Session. Great format. These Docs all know their data! Each with a different interpretation My main takeaway: as @rubinstein_md quoted "these and those" are all valid approaches https://t.co/ZNAUoykIbE
-
Excited to share our paper published in @LeukemiaJnl “Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials” https://t.co/o5ZHZh0oxe We were interested to look at treatment patterns during the era of the early ibrutinib trials 🧵 1/n